Metabolic aspects of psoriasis

References

• Watson W, Cann HM, Farber EM, et al. The genetics of psoriasis. Arch Dermatol 1972;105:197–207
   PubMedGoogle Scholar
• Braverman IM, Yen A. Microcirculation in psoriatic skin. J Invest Dermatol 1974;62:493–502
   PubMed Web of Science ®Google Scholar
• Guilhou JJ, Meynadier M, Clot J. New concepts in the pathogenesis of psoriasis. Br J Dermatol 1978;98:585–92
   PubMed Web of Science ®Google Scholar
• Voorhees JJ. Molecular mechanisms and pharmacological modulation in psoriasis. In: Clark FH, ed. Annual reports in medicinal chemistry. Vol 12, chap 17. New York: Academic Press, 1977:162–71
   Google Scholar
• Voorhees JJ, Duell EA, Creehan P, et al. Cyclic AMP and cyclic GMP in epidermal physiology and pathophysiology. In: Mali JW, ed. Current problems in dermatology. Vol 6. Basel: Karger, 1976: 107–53
   Google Scholar
• Voorhees JJ, Duell EA, Bass LJ, et al. Decreased cyclic AMP in the epidermis of lesions of psoriasis. Arch Dermatol 1972;105:695–701
   PubMed Web of Science ®Google Scholar
• Voorhees JJ, Colburn NH, Stawiski M, et al. Imbalanced cyclic AMP and cyclic GMP levels in the rapidly dividing, incompletely differentiated epidermis of psoriasis. In: Clarkson B, Baserga R, eds. Control of proliferation in animal cells. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1974:635–48
   Google Scholar
• Voorhees JJ, Chambers DA, Duell EA, et al. Molecular mechanisms in proliferative skin disease. J Invest Dermatol 1976; 67:442–50
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Adachi K, Halprin KM, et al. On the lack of response to catecholamine stimulation by the adenyl cyclase system in psoriatic lesions. Br J Dermatol 1975;92:619–24
   PubMed Web of Science ®Google Scholar
• Aso K, Orenberg EK, Farber EM. Reduced epidermal cyclic AMP accumulation following prostaglandin stimulation: its possible role in the pathophysiology of psoriasis. J Invest Dermatol 1975;65:375–8
   PubMed Web of Science ®Google Scholar
• Skott A, Mobacken H, Starmark JE. Exacerbation of psoriasis during lithium treatment. Br J Dermatol 1977;96:445–8
   PubMed Web of Science ®Google Scholar
• Sondergaard J, Wadskov S, Jensen HA, et al. Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm Venereol (Stockh) 1976;56:239–43
   Google Scholar
• Wiley H, Weinstein G. Selective proliferative abnormality induced by propranolol in uninvolved psoriatic skin compared to normal skin. J Invest Dermatol 1977;68:239
   Web of Science ®Google Scholar
• Marcelo CL, Duell EA, Stawiski MA, et al. Cyclic nucleotide levels in psoriatic and normal keratomed epidermis. J Invest Dermatol 1979;72:20–4
   PubMed Web of Science ®Google Scholar
• Stawiski MA, Powell JA, Lang PG, et al. Papaverine: its effects on cyclic AMP in vitro and psoriasis in vivo. J Invest Dermatol 1975;64:124–7
   PubMed Web of Science ®Google Scholar
• Rusin LJ, Duell EA, Voorhees JJ. Papaverine and RO 20–1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro. J Invest Dermatol 1978;71:154–6
   PubMed Web of Science ®Google Scholar
• Russell DH, Combest WL, Duell EA, et al. Glucocorticoid inhibits elevated polyamine biosynthesis in psoriasis. J Invest Dermatol 1978;71:177–81
   PubMed Web of Science ®Google Scholar
• Voorhees JJ. Pathophysiology of psoriasis. Annu Rev Med 1977;28:467–73
   PubMed Web of Science ®Google Scholar
• Goerz G, Orfanos CE. Systemic treatment of psoriasis with a new aromatic retinoid: preliminary evaluation of a multicenter controlled study in the Federal Republic of Germany. Dermatologica 1978;157(Suppl):38–44
   PubMedGoogle Scholar
• Puck TT. Cyclic AMP, the microtubule-microfilament system, and cancer. Proc Natl Acad Sci USA 1977;74:4491–5
   PubMed Web of Science ®Google Scholar
• Voorhees JJ. Cyclic nucleotides, arachidonic acid and polyamines in the pathophysiology of inflammatory proliferative skin diseases. In Safai B, Good RA, eds. Immunodermatology. New York: Plenum Press, 1978 (in press)
   Google Scholar
• Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979;300:1142–7
   PubMed Web of Science ®Google Scholar
• Cantieri JS, Graff G, Goldberg ND. Cyclic GMP metabolism in psoriasis: activation of soluble epidermal guanylate cyclase by arachidonic acid and 12-hydroxy-5,8,10,14-eicosatetraenoic acid. J Invest Dermatol 1980;74:234–7
   PubMed Web of Science ®Google Scholar
• Hammarstrom S, Hamberg M, Duell EA. Glucocorticoid in inflammatory proliferative skin disease reduces arachidonic and hydroxyeicosatetraenoic acids. Science 1977;197:994–6
   PubMed Web of Science ®Google Scholar
• Voorhees JJ. A new concept of the anti-inflammatory action of topical steroids. New York: Science & Medicine Publishing Co, 1977:1–19
   Google Scholar
• Voorhees JJ, Marcelo CU Duell EA. Cyclic AMP, cyclic GMP, and glucocorticoids as potential metabolic regulators of epidermal proliferation and differentiation. J Invest Dermatol 1975;65:179–90
   PubMed Web of Science ®Google Scholar
• Grosshans E, Henry M, Bohlen F, et al. Skin polyamine levels in psoriasis—the effect of therapy. J Invest Dermatol 1978;70:227
   Web of Science ®Google Scholar
• Black AK, Greaves MW, Hensby CN, et al. Increased prostaglandins E2 and F2alpha in human skin at 6 and 24 h after ultraviolet beta irradiation (290–320 nm). Br J Clin Pharmacol 1978;5(5):431–6
   PubMed Web of Science ®Google Scholar
• Henderson GB, Zevely EM, Huennekens FM. Cyclic adenosine 3′:5′-monophosphate and methotrexate transport in L1210 cells. Cancer Res 1978;38:859–61
   PubMed Web of Science ®Google Scholar